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A B S T R A C T
Purpose
Non–small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical
outcome have been achieved. The issue is critical for stage I patients for whom there are no
available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy.
We aimed to find DNA methylation markers that could be helpful in this regard.
Patients and Methods
A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA
obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA
methylation markers were validated by a single-methylation pyrosequencing assay in an indepen-
dent cohort of 143 patients with stage I NSCLC.
Results
Unsupervised clustering of the 10,000 most variable DNAmethylation sites in the discovery cohort
identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard
ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P .004). The study in the validation cohort of the significant
methylated sites from the discovery cohort found that hypermethylation of five genes was
significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1,
ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished
patients with high- and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P  .001).
Conclusion
The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be
practically determined by user-friendly polymerase chain reaction assays. The analysis of the best
DNA methylation biomarkers improved prognostic accuracy beyond standard staging.
J Clin Oncol 31:4140-4147. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Non–small-cell lung cancer (NSCLC) is the leading
cause of cancer-related death.1 The poor prognosis
of patients with NSCLC is associated with several
factors, among which are late disease diagnosis and
the small number of effective drugs. The absence of
validated prognostic biomarkers could also be rele-
vant, because even patients with stage I NSCLC who
undergo potentially curative surgical resection are at
high risk of dying from recurrent disease, with a
5-year relapse rate of 35% to 50%.1 Although adju-
vant platinum-based chemotherapy is beneficial in
more advanced resected disease, in which most of
the patients have a high risk of recurrence,2-6 it has
failed to show a survival benefit for patients at stage
I.7,8 One explanation for these negative data in the
early stages could be the lack of biologic factors pre-
dicting their recurrence and the fact that, in the
absence of useful biomarkers, all stage I NSCLCs are
pooled, making it more difficult to draw meaningful
clinical conclusions.
In the search for new potential biomarkers of
human cancer, the hypermethylation of the CpG
island sequences located in the promoter regions of
tumor suppressor genes are gaining prominence.9-11
We wondered whether DNA methylation markers
could also be used to provide a prognostic snapshot
of lung tumors. Herein, we have obtained DNA
methylation signatures associated with shorter
relapse-free survival (RFS) in stage I NSCLCs that
could be useful in the design of clinical trials for
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adjuvant chemotherapy in the expanding population of those diag-
nosed with early-stage lung cancer.
PATIENTS AND METHODS
Study Design and Patient Population
Patients were eligible to enter the study as part of either discovery or
validation cohorts if they underwent surgical resection of NSCLC in any of the
international participating institutions. Patients treated with neoadjuvant
therapy and/or patients with large cell-carcinoma were not included in the
study. The clinical characteristics of the NSCLC surgical samples obtained are
provided in Table 1. Descriptors of the patients by site of origin and for each
single case are included in the Data Supplement. Tumors were collected by
surgical resection from patients who provided consent and under approval by
the institutional review boards. The median clinical follow-up was 7.2 years.
Follow-up was performed by using radiographic imaging (chest x-ray and
computed tomography scans), and time of recurrence was noted. In addition,
25 histologically normal lung tissue counterparts without any histologic evi-
dence of malignancy were also analyzed (Data Supplement). The NSCLC
tumor samples were studied in a consecutive manner as they arrived at the
centralized DNA methylation facility and passed the technical quality checks.
Procedures
The DNA methylation status of 450,000 CpG sites was established by
using the Infinium 450K Methylation Array.12,13 The methylation score of
Table 1. Clinical Characteristics of the Discovery and Validation Cohorts
Characteristic
Discovery Cohort
(n  444)
Subset From
Discovery Cohort
for RFS Analysis
(n  198)
Subset From
Discovery Cohort
for RFS Analysis
(stage I) (n  147)
Validation Cohort
(stage I) (n  143)†
No. % No. % No. % No. %
Age, years
Median 65 65.5 65.9 63.7
Range 35-90 38-85 38-85 32-78
Sex
Male 254 57 107 54 78 53 126 88
Female 190 43 91 46 69 47 17 12
Smoking history
Current or former smoker 334 75 169 85 127 86 122 85
Nonsmoker 47 11 25 13 17 12 10 7
Unknown 63 14 4 2 3 2 11 8
Disease stage
I 237 53 147 74 147 100 143 100
II 94 21 22 11 0 0 0 0
III 102 23 26 13 0 0 0 0
IV 11 3 3 2 0 0 0 0
Tumor type
Adenocarcinoma 322 73 155 78 118 80 79 55
Squamous cell carcinoma 122 27 43 22 29 20 64 45
Thoracic surgery practice
Lobectomy 396 90 172 86 132 90 117 82
Pneumonectomy 23 5 13 7 3 2 3 2
Segmentectomy 24 5 13 7 12 8 2 1
Unknown 1 0 0 0 0 0 21 15
Adjuvant treatment
None 211 48 198 100 147 100 143 100
Chemotherapy 24 5 0 0 0 0 0 0
Chemotherapy plus radiotherapy 12 3 0 0 0 0 0 0
Radiotherapy 27 6 0 0 0 0 0 0
Unknown 170 38 0 0 0 0 0 0
Recurrence
Yes 161 36 98 49 53 36 51 36
No 150 34 100 51 94 64 92 64
Unknown 133 30 0 0 0 0 0 0
RFS, months
Average 46.7 50.8 60.7 42.3
Range 0.6-224 0.6-224 0.6-224 2.6-130
Origin of the samples
Europe 291 66 100 51 68 46 142 99
United States 153 34 98 49 79 54 1 1
Abbreviation: RFS, relapse-free survival.
Patients from the discovery cohort who had undergone resection of non–small-cell lung cancer and did not receive adjuvant chemotherapy before relapse.
†All patients from the validation cohort had undergone resection of non–small-cell lung cancer and did not receive adjuvant chemotherapy before relapse.
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each CpG is represented as a  value. Samples were clustered in an unsuper-
vised manner by using the 10,000 most variable values for CpG methylation
according to the standard deviation for the CpG sites located in promoter
regions by hierarchical clustering using the complete method for agglomerat-
ing the Manhattan distances (Data Supplement). DNA methylation microar-
ray data are available from the National Center for Biotechnology
Information’s Gene Expression Omnibus.14 Pyrosequencing analyses to de-
termine CpG methylation status were conducted as previously described.15
Statistical Analysis
Assay results were compared with patient outcomes in a double-blind
manner. Median follow-up duration was calculated according to the inverse
Kaplan-Meier method. Differences in distributions between groups were ex-
amined by the 2 test. The Kaplan-Meier method was used to estimate RFS,
and differences among the groups were analyzed with the log-rank test. Hazard
ratios (HRs) from univariate Cox regression analysis were used to determine
the association of clinicopathologic features with relapse. Multivariate Cox
proportional hazards regression was used to evaluate independent prognostic
factors associated with RFS.
RESULTS
Characteristics of Patients in the Discovery Cohort
Clinical characteristics of the 444 patients in the discovery cohort
are listed in Table 1. Descriptors of the patients by site of origin and for
each single case are shown in the Data Supplement. The clinicopath-
ologic characteristics of the lung tumors studied were related to the site
of origin (United States v Europe).16-18
DNA Methylation Profiles Identify Two Groups With
Different RFS Rates
We first evaluated a genome-wide DNA methylation profile of
the original cohort of 444 patients with lung tumors, which included
two NSCLC subtypes (adenocarcinoma and squamous cell carcino-
mas) by using a previously validated 450,000 CpG methylation mi-
croarray.12,13 In addition, 25 histologically normal lung tissue
counterparts without any histologic evidence of malignancy were also
analyzed (Data Supplement).
The analyses of CpG methylation values from the DNA meth-
ylation microarray within all primary NSCLCs (n 444) and histo-
logically normal tissues (n  25) identified 10,000 promoter CpGs
with the most variable CpG methylation levels (Data Supplement).
These 10,000 top-ranked CpG sites were plotted in an unsupervised
manner in the 444 primary NSCLCs (Fig 1A). The hierarchical clus-
tering distinguished two main types of tumors that accounted for 70
(16%; group A) and 374 (84%; group B) patients. The2 tests showed
a significantly higher proportion of the adenocarcinoma histologic
type in group A (2 test P  .02), but no other significant differ-
ences in the distribution of the tumors according to stage, sex, or
smoking history between group A and group B were observed
(Data Supplement).
We investigated whether these two DNA methylation groups had
any effect on the RFS of these patients. We analyzed the subset of
patients who had undergone resection of NSCLC and had not received
adjuvant chemotherapy before relapse, because of the possible con-
founding effect of chemotherapy on the RFS. Overall survival was not
selected as an end point for the study because it could be affected by
subsequent therapies received at relapse. Overall, 198 patients with
NSCLC met the criteria for inclusion in the RFS cohort. Most impor-
tantly, these group A patients with NSCLC had a significantly shorter
RFS, as shown in the Kaplan-Meier survival analysis (log-rank test
P  .001; Fig 1B) and in the univariate (HR, 2.45; P  .001) and
multivariate (HR, 2.40; P  .001) Cox regression analyses of stage,
histology, smoking history, age, and sex (Data Supplement). In refer-
ence to histology, the unsupervised clustering analysis of either ade-
nocarcinomas or squamous cell carcinomas also identified a group
associated with shorter RFS (HR, 2.47; P  .002 and HR 4.93; P 
.001, respectively; Data Supplement).
We wanted to extend these observations to identify those NSCLC
tumors that, despite their low stage, are prone to recurrence. The
selection of these patients is critical because approximately 30% to
40% of patients with stage I NSCLC die of recurrent disease.19-21 To
address this, the profile of the aforementioned 10,000 promoter CpGs,
which had already shown their prognostic value throughout all
NSCLC stages, was plotted in an unsupervised manner in the 237
patients with stage I NSCLC (Fig 1C). Hierarchical clustering distin-
guished two main types of tumors, accounting for 63 (27%; group 1)
and 174 (73%; group 2) patients. The 2 tests revealed no significant
differences in the distribution of the tumors in the two groups by sex,
smoking history, and histologic type (Data Supplement). Among the
237 patients with stage I NSCLC, 147 met the described criteria for
inclusion in the RFS cohort. The ineligible patients (n 90) did not
show a higher recurrence rate (2 test P  .12). Group 1 identified
patients with high-risk stage I NSCLC that had lower RFS, as revealed
by the Kaplan-Meier survival analysis (log-rank test P .03; Fig 1D)
and in the univariate (HR, 1.85; P .037) and multivariate (HR, 2.35;
P .004) Cox regressions of histology, smoking history, age, and sex
(Data Supplement). In reference to histology, the unsupervised clus-
tering analysis of the adenocarcinomas in stage I also identified a
group associated with shorter RFS (HR, 2.94; P .003; Data Supple-
ment), and a trend was observed for squamous cell carcinomas (HR,
2.55; P .09; Data Supplement). We also performed a Cox analysis
that included smoking pack-years as a covariate. We categorized pack-
years22 as less than 30 or  30. The inclusion of the pack-year data
value did not change the significant association of group 1 tumors with
shorter RFS (HR, 2.3; P  .007). For all the patients with stage I
NSCLC (because stage IA and IB have different outcomes), we also
added this particular feature (according to the sixth revision of the
TNM classification criteria) to the Cox regression multivariate analy-
sis and group 1 remained significantly associated with shorter RFS
(HR, 2.12; P .018). The inclusion of tumor size within stage I (also
an indicator of poor prognosis in NSCLC) in the Cox analysis did not
alter the significant association of group 1 tumors with shorter RFS
(HR, 2.02; P .05). The reclassification of the stage I tumors accord-
ing to the seventh revision of the TNM classification criteria also
confirmed that group 1 patients remained significantly associated
with shorter RFS (HR, 2.14; P .05).
Identification of Candidate Genes as DNA Methylation
Biomarkers of Shorter RFS in the Discovery Cohort of
Stage I NSCLC
The identification of a DNA methylation signature for stage I
NSCLC that predicts early recurrence might be useful, but the
finding of a smaller panel of DNA methylation biomarkers could
simplify the process. To achieve this goal, we developed an integra-
tive approach to rank the CpG sites that, according to their meth-
ylation status ( values), were best at discriminating the 444
NSCLC samples from the 25 histologically normal lung tissue
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samples. This analysis identified 338 highly ranked CpG sites (Data
Supplement). From these, we focused on the CpGs located in
regulatory regions: promoter CpG islands9-11 and shores.23,24 We
found that 150 of the 338 CpG sites were located in the described
regions. All of these 150 CpG sites were present in the 10,000 CpG
sites used in the clustering. CpG hypermethylation of these 150
sites was significantly enriched in group A versus group B (t test
P .001) and in group 1 versus group 2 (t test P .001), support-
ing their potential prognostic value. Thus, we tested the methyl-
ation value of each of these 150 CpG sites for RFS in the 147 stage I
tumors by Kaplan-Meier survival and multivariate Cox regression.
We identified 54 CpGs corresponding to 42 genes that were signif-
icantly associated with shorter RFS at a 10% false discovery rate
(Data Supplement). Our data mining approach can be comple-
mented by others and, in this regard, the promoter CpG sites of
other methylation markers in lung cancer25 did not pass the criteria
used. However, we confirmed that CDH13 and RASSF1A hyper-
methylation was associated with shorter RFS (HR, 3.47; P  .01
and HR, 2.17; P .02, respectively) in the 147 stage I tumors.
Validation of Candidate Genes as DNA Methylation
Biomarkers of Shorter RFS in an Independent Cohort
of Stage I NSCLC
Once we had identified 42 genes with CpG promoter methyl-
ation that influenced RFS in our initial discovery cohort of 147 stage I
tumors, we sought to validate these single DNA methylation markers
in an additional cohort of 143 patients with stage I NSCLC (Table 1).
Descriptors of the patients by site of origin and for each single sample
are shown in the Data Supplement. All these new NSCLC samples
were obtained from patients who had undergone a resection and did
not receive adjuvant chemotherapy. The validation cohort, in com-
parison to the discovery set, was significantly enriched in European
samples and, thus, in affected men and squamous cell carcinomas.16,17
The methylation levels at the described CpG sites were analyzed by
pyrosequencing15 to test a more affordable large-scale approach.
Methylation value by pyrosequencing was obtained from the average
of each of the CpG dinucleotides included in the sequence analyzed
(Data Supplement). Because the DNA material was limited, we
selected the top 10 genes (Data Supplement) with an HR of more than
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Fig 1. DNA methylation signatures associated with recurrence-free survival (RFS) in non–small-cell lung cancer samples. (A) Unsupervised hierarchical clustering and
heat map associated with the methylation profile (according to the color scale shown) of the 444 primary tumor specimens based on the 10,000 most variable promoter
 values. Two different histologic subtypes are represented: adenocarcinoma (Adeno; red) and squamous cell carcinoma (yellow). Each column represents an individual
patient and each row an individual CpG. (B) Kaplan-Meier analysis for RFS among the 198 patients with RFS information according to the two groups obtained from
the clustering. The P value corresponds to the hazard ratio (HR) adjusted by multivariate regression (including age, sex, smoking history, stage, and histologic type).
(C) Unsupervised clustering and the heat map of the subset of 237 patients with stage I non–small-cell lung cancer. (D) Kaplan-Meier estimates for RFS among the
subset of 147 patients with RFS information according to the two groups obtained in the clustering. The P value reflects the HR adjusted as in the analysis in (B).
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2 at a 10% false discovery rate (Data Supplement). By histology, four
(80%) of the top five candidates in the adenocarcinoma set were also
present in the overall 10-gene candidate list (Data Supplement).
Of these 10 candidate DNA methylation biomarkers associated
with recurrence in the discovery cohort by using the DNA methylation
microarray, five (50%) were significantly associated with recurrence
(P .05) in the validation cohort of 143 stage I NSCLC samples analyzed
by pyrosequencing. These were the genes histone cluster1 H4F
(HIST1H4F; HR, 3.55; P .001), protocadherin gamma subfamily B6
(PCDHGB6; HR, 2.95; P  .002), neuropeptide B/W receptor 1
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Fig 2. Kaplan-Meier estimates of relapse-
free survival in patients with stage I non–
small-cell lung cancer. Patients bymethylation
status of the five validated genes. (A, C, E, G,
I) Kaplan-Meier estimates for relapse-free sur-
vival of the final five validated genes in the
subset of 147 patients in stage I from the
discovery cohort. Methylation status was
determined by the Infinium 450k Methyl-
ation Array. (B, D, F, H, J) Corresponding
Kaplan-Meier estimates for the same
genes in the 143 patients in stage I in-
cluded in the validation cohort. In this
case, methylation status was determined
by pyrosequencing. The P values corre-
spond to hazard ratios (HRs) adjusted by
multivariate regression (including age,
sex, smoking history, and histologic type).
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(NPBWR1; HR, 2.71; P .004), ALX homeobox protein 1 (ALX1; HR,
2.29;P .015),andhomeoboxA9(HOXA9;HR,2.03;P .027;Fig2and
Data Supplement). In addition, three other genes (30%) showed a trend
toward significance (OTX2; HR, 1.82; P .11; TRIM58; HR, 1.57; P
.14; and TRH; HR, 4.23; P .17; Data Supplement). The pyrosequencing
values for the five significant genes (HIST1H4F, PCDHGB6,
NPBWR1, ALX1, and HOXA9) in all studied samples, histologi-
cally normal tissues (n 25), and primary NSCLC (n 143) are
provided in the Data Supplement.
We also observed a greater risk of shorter RFS, according to Kaplan-
Meier plots, when stage I NSCLCs harbored a large number of the
five statistically significant hypermethylated markers (HIST1H4F,
PCDHGB6, NPBWR1, ALX1, and HOXA9). To obtain the most useful
methylation signature, we chose the cutoff of zero to one versus two or
morehypermethylatedmarkers,because itwas thebestone inresembling
the percentage of expected recurrences.1,19-21 The described methylation
signature divides the patients with stage I tumors into two arms: patients
withzerotoonemethylatedmarkersthatshowlongerRFSandthosewith
two or more hypermethylated genes that were associated with a higher
risk of poor RFS by Kaplan-Meier estimates (Fig 3A). The heavily hyper-
methylated group identified patients with high-risk stage I NSCLC who
had shorter RFS, as shown by the Kaplan-Meier survival analysis (log-
rank test P .010; Fig 3A) and the univariate (HR, 2.26; P .012) and
multivariate (HR, 3.24; P .001) Cox regressions (Data Supplement).
The identified methylation signature remained significantly associated
with shorter RFS in the Cox regression multivariate analysis, even when
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Fig 3. (A-B) Kaplan-Meier estimates of relapse-free survival by number ofmethylated genes and (C) forest plot with hazard ratios for recurrence in stage I non–small-cell lung cancer.
(A, B) In each panel, patients are grouped into methylation low (blue) or methylation high (gold) groups according to the number of methylated genes (zero to one v two to five) from
the five-gene signature (including HIST1H4F, NPBWR1, PCDHGB6, ALX1, and HOXA9). (A) Patients from the validation cohort analyzed by pyrosequencing. (B) Patients from the
discovery cohort analyzed by the DNAmethylationmicroarray. The P values correspond to hazard ratios (HRs) adjusted bymultivariate regression (including age, sex, smoking history,
and histologic type). (C) The forest plot shows the multivariate Cox regression for the various DNAmethylation classifiers of patients with stage I non–small-cell lung cancer. Data for
the group1heatmap in stage Iwere obtained from thediscovery cohortwith the 450K array.Data fromeachof the five significant genes and the zero to one v twohypermethylated
genes signaturemodelwere obtained fromboth the discovery cohortwith the 450K array and the validation cohort by pyrosequencing. The prognostic value for each gene or signature
was adjusted for age, sex, smoking history, and histologic type.
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stage I tumors were subdivided into IA and IB according to the sixth
revision of the TNM classification (HR, 3.09; P .002). The reclassifica-
tion of the stage I tumors according to the seventh revision of the TNM
classification criteria also confirmed the relevance of the enriched hyper-
methylationgroupforshorterRFSin103originalstageItumorsforwhich
all the necessary clinicopathologic information was available (HR, 2.89;
P .010). The inclusion of tumor size in the Cox analysis within stage I
did not alter the significant association of tumors with two or more
methylated markers with shorter RFS (HR, 2.88; P .011). Because 80%
of recurrences of stage I NSCLC occur within 3 years of surgery,19 we also
calculated how many patients relapsed in this period. We observed that
48% (95% CI, 39.8% to 56.4%) of patients from the enriched methylated
group relapsed, but only 18% (95% CI, 16.1% to 19.5%) of those in the
low methylated group (zero to one methylated markers). Finally, as ex-
pected, the prognostic zero to one versus two or more hypermethylated
genes signature obtained by pyrosequencing in the validation cohort was
alsoobservedinthe147stageINSCLCsfromthediscoverycohortstudied
bytheDNAmethylationmicroarray(HR,1.95;P .023;Fig3B).Overall,
we have identified DNA methylation classifiers that, at a different level of
resolution, are potential prognostic biomarkers of shorter RFS in stage I
NSCLC (Fig 3C).
DISCUSSION
One challenge in lung cancer management is that, despite complete
surgical resection, patients with early-stage NSCLC are at considerable
risk of recurrence and death. For this reason, we studied samples from
stage I patients with the aim of identifying candidate DNA methyl-
ation biomarkers that can distinguish between patients at low risk of
relapse and those at high risk for whom adjuvant treatment could be
prescribed. Our results have distinguished two prognostic groups of
stage I NSCLC at two levels of resolution by using a DNA methylation
microarray profile that includes 10,000 CpG sites and by obtaining a
methylation signature based on five genes derived from Cox regres-
sion models that could simplify the decision-making process.
Our study represents the largest cohort of primary NSCLCs stud-
ied for high-resolution DNA methylation analyses with a clinical ori-
entation, a complement to the genomics26 and expression27 data.
Other genomic approaches with lower resolution have determined
DNA methylation profiles in NSCLCs,15,28-32 although they have not
focused on stage I. Candidate gene approaches have also suggested
DNA methylation markers that are linked with prognosis in
NSCLC.25,33 An example is provided by the suggested association
between p16INK4a, CDH13, RASSF1A, and APC hypermethylation
and early recurrence in stage I lung cancer.25 In addition, some CpG
methylation events may be associated with better prognosis,34 and
their identification will require further analyses. It is also noteworthy
to explain that useful hypermethylated markers to add to those char-
acterized herein are possible and can be obtained from further mining
of our publically available DNA methylation data.
Among the genes in our five-gene methylation signature,
HOXA9 hypermethylation has been described in lung tumorigene-
sis.29,35,36 Although the association of HOXA9 methylation with RFS
was not assessed, HOXA9 hypermethylation relates to poor prognosis
in other tumor types.37,38 For the other genes, PCDHGB6 and
NPBWR1 hypermethylation occur in breast39 and prostate40 cancer,
respectively, and both are associated with poor prognosis. Although
our analysis was not aimed at finding markers of chemoresponse, the
observed CpG hypermethylation of a particular histone gene in the
high-risk group (HIST1H4F) warrants further research because a
small subset of patients with NSCLC are sensitive to histone deacety-
lase inhibitors.41 The identified patients with lung cancer whose high
risk is associated with the described DNA methylation markers might
also be a candidate group to receive DNA demethylating agents.42
The introduction of new therapies in NSCLC, such as epidermal
growth factor receptor and anaplastic lymphoma kinase inhibitors, is a
promising avenue for improving the outcome of these patients, but the
target population is small. Although surgery remains the reference treat-
ment in stage I NSCLCs, recurrence of the disease still occurs. Adjuvant
platinum-based chemotherapy is beneficial in stage II and IIIa NSCLC.2-6
Most studies have failed to show a survival benefit for adjuvant chemo-
therapy in stage I,7,8 although a trend was observed for stage IB.7,8 How-
ever,nomolecularbiomarkerswereinvestigatedinthosetrials.Ifwecould
identify stage I NSCLCs associated with shorter RFS, we could design
stage-specific clinical trials in which a benefit of adjuvant therapies could
accrue to the high-risk population. The DNA methylation markers iden-
tified herein, once they have been externally validated, could be useful for
generating treatment guidelines for early-stage lung tumors.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Although all authors completed the disclosure declaration, the following
author(s) and/or an author’s immediate family member(s) indicated a
financial or other interest that is relevant to the subject matter under
consideration in this article. Certain relationships marked with a “U” are
those for which no compensation was received; those relationships marked
with a “C” were compensated. For a detailed description of the disclosure
categories, or for more information about ASCO’s conflict of interest policy,
please refer to the Author Disclosure Declaration and the Disclosures of
Potential Conflicts of Interest section in Information for Contributors.
Employment or Leadership Position: None Consultant or Advisory
Role: None Stock Ownership: None Honoraria: John K. Field, Chinese
Cancer Association 2013, 14th European Lung Cancer Congress 2013,
5th Asia Pacific Lung Cancer Conference 2012 Research Funding: None
Expert Testimony: None Patents: None Other Remuneration: None
AUTHOR CONTRIBUTIONS
Conception and design: Juan Sandoval, Jesus Mendez-Gonzalez,
Manel Esteller
Provision of study materials or patients: Ernest Nadal, Montse
Sanchez-Cespedes, Josefina Mora, Lucia A. Muscarella, Marina Pollan,
Luis Montuenga, Elisabeth Brambilla, John K. Field, Luca Roz, Giorgio
V. Scagliotti, David Beer
Collection and assembly of data: Juan Sandoval, Jesus
Mendez-Gonzalez, Ernest Nadal, Guoan Chen, F. Javier Carmona, Sergi
Sayols, Sebastian Moran, Holger Heyn, Miguel Vizoso, Antonio Gomez,
Montse Sanchez-Cespedes, Christoph Bock, Miquel Taron, Josefina
Mora, Lucia A. Muscarella, Triantafillos Liloglou, Michael Davies,
Marina Pollan, Maria J. Pajares, Wenceslao Torre, Luis M. Montuenga,
Elisabeth Brambilla, John K. Field, Luca Roz, Marco Lo Iacono, Giorgio
V. Scagliotti, Rafael Rosell, David G. Beer, Manel Esteller
Data analysis and interpretation: Juan Sandoval, Jesus
Mendez-Gonzalez, Antonio Gomez, Yassen Assenov, Fabian Mu¨ller,
Christoph Bock, Manel Esteller
Manuscript writing: All authors
Final approval of manuscript: All authors
Sandoval et al
4146 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
from 130.192.222.19
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on June 21, 2016
Copyright © 2013 American Society of Clinical Oncology. All rights reserved.
REFERENCES
1. Siegel R, Naishadham D, Jemal A: Cancer
statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Scagliotti GV, Fossati R, Torri V, et al: Ran-
domized study of adjuvant chemotherapy for com-
pletely resected stage I, II, or IIIA non-small-cell lung
cancer. J Natl Cancer Inst 95:1453-1461, 2003
3. Waller D, Peake MD, Stephens RJ, et al:
Chemotherapy for patients with non-small cell lung
cancer: The surgical setting of the Big Lung Trial. Eur
J Cardiothorac Surg 26:173-182, 2004
4. Winton T, Livingston R, Johnson D, et al: Vinore-
lbine plus cisplatin vs. observation in resected non-small-
cell lung cancer. N Engl J Med 352:2589-2597, 2005
5. Douillard JY, Rosell R, De Lena M, et al: Adjuvant
vinorelbine plus cisplatin versus observation in patients
with completely resected stage IB-IIIA non-small-cell
lung cancer (Adjuvant Navelbine International Trialist As-
sociation [ANITA]): A randomised controlled trial. Lancet
Oncol 7:719-727, 2006
6. ArriagadaR,DunantA, PignonJP, et al: Long-term
results of the international adjuvant lung cancer trial
evaluating adjuvant cisplatin-based chemotherapy in re-
sected lung cancer. J Clin Oncol 28:35-42, 2010
7. Pignon JP, Tribodet H, Scagliotti GV, et al:
Lung adjuvant cisplatin evaluation: A pooled analysis
by the LACE Collaborative Group. J Clin Oncol
26:3552-3559, 2008
8. Strauss GM, Herndon JE 2nd, Maddaus MA,
et al: Adjuvant paclitaxel plus carboplatin compared
with observation in stage IB non-small-cell lung
cancer: CALGB 9633 with the Cancer and Leukemia
Group B, Radiation Therapy Oncology Group, and
North Central Cancer Treatment Group Study
Groups. J Clin Oncol 26:5043-5051, 2008
9. Herman JG, Baylin SB: Gene silencing in
cancer in association with promoter hypermethyl-
ation. N Engl J Med 349:2042-2054, 2003
10. Esteller M: Epigenetics in cancer. N Engl
J Med 358:1148-1159, 2008
11. Baylin SB, Jones PA: A decade of exploring
the cancer epigenome: Biological and translational
implications. Nat Rev Cancer 11:726-734, 2011
12. Sandoval J, Heyn H,Moran S, et al: Validation of a
DNAmethylationmicroarray for 450,000CpGsites in the
human genome. Epigenetics 6:692-702, 2011
13. Bibikova M, Barnes B, Tsan C, et al: High
density DNA methylation array with single CpG site
resolution. Genomics 98:288-295, 2011
14. National Center for Biotechnology Information:
GeneExpressionOmnibus.http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?accGSE39279
15. Fernandez AF, Assenov Y, Martin-Subero JI,
et al: A DNA methylation fingerprint of 1628 human
samples. Genome Res 22:407-419, 2012
16. Travis WD, Brambilla E, Muller-Hermlink HK,
et al: Pathology and genetics of tumours of the lung,
pleura, thymus and heart, in, World Health Organi-
zation (eds): Classification of Tumours, Lyon,
France, IARC Press, 2004
17. CuradoMP, Edwards B, Shin HR, et al: Cancer
Incidence in Five Continents, Vol IX. Lyon, France,
International Agency for Research on Cancer (IARC)
Scientific Publication 160, 2007
18. Janssen-Heijnen ML, Coebergh JW: The
changing epidemiology of lung cancer in Europe.
Lung Cancer 41:245-258, 2003
19. Martini N, Bains MS, Burt ME, et al: Incidence
of local recurrence and second primary tumors in
resected stage I lung cancer. J Thorac Cardiovasc
Surg 109:120-129, 1995
20. Mountain CF: Revisions in the International Sys-
tem for Staging Lung Cancer. Chest 111:1710-1717,
1997
21. Hoffman PC, Mauer AM, Vokes EE. Lung
cancer. Lancet 355:479-485, 2000
22. Fujisawa T, Iizasa T, Saitoh Y, et al: Smoking
before surgery predicts poor long-term survival in
patients with stage I non-small-cell lung carcinomas.
J Clin Oncol 17:2086-2091, 1999
23. Irizarry RA, Ladd-Acosta C, Wen B, et al: The
humancolon cancermethylomeshowssimilar hypo- and
hypermethylation at conserved tissue-specific CpG is-
land shores. Nat Genet 41:178-186, 2009
24. Hansen KD, Timp W, Bravo HC, et al: In-
creased methylation variation in epigenetic domains
across cancer types. Nat Genet 43:768-775, 2011
25. BrockMV,HookerCM,Ota-MachidaE, et al: DNA
methylation markers and early recurrence in stage I lung
cancer. N Engl J Med 358:1118-1128, 2008
26. Cancer Genome Atlas Research Network:
Comprehensive genomic characterization of squa-
mous cell lung cancers. Nature 489:519-525, 2012
27. Kratz JR, He J, Van Den Eeden SK, et al: A
practical molecular assay to predict survival in re-
sected non-squamous, non-small-cell lung cancer:
Development and international validation studies.
Lancet 379:823-832, 2012
28. Brena RM, Morrison C, Liyanarachchi S, et al:
Aberrant DNA methylation of OLIG1, a novel prog-
nostic factor in non-small cell lung cancer. PLoS
Med 4:e108, 2007
29. Rauch T, Wang Z, Zhang X, et al: Homeobox
gene methylation in lung cancer studied by genome-
wide analysis with a microarray-based methylated
CpG island recovery assay. Proc Natl Acad Sci U S A
104:5527-5532, 2007
30. Christensen BC, Marsit CJ, Houseman EA, et
al: Differentiation of lung adenocarcinoma, pleural
mesothelioma, and nonmalignant pulmonary tissues
using DNA methylation profiles. Cancer Res 69:
6315-6321, 2009
31. Selamat SA, Chung BS, Girard L, et al:
Genome-scale analysis of DNA methylation in lung
adenocarcinoma and integration with mRNA expres-
sion. Genome Res 22:1197-1211, 2012
32. Heller G, Babinsky VN, Ziegler B, et al:
Genome-wide CpG island methylation analyses in
non-small cell lung cancer patients. Carcinogenesis
34:513-521, 2013
33. Toyooka S, Suzuki M, Maruyama R, et al: The
relationship between aberrant methylation and sur-
vival in non-small-cell lung cancers. Br J Cancer
91:771-774, 2004
34. Claus R, Lucas DM, Stilgenbauer S, et al:
Quantitative DNA methylation analysis identifies a
single CpG dinucleotide important for ZAP-70 ex-
pression and predictive of prognosis in chronic lym-
phocytic leukemia. J Clin Oncol 30:2483-2491, 2012
35. Son JW, Jeong KJ, JeanWS, et al: Genome-wide
combination profiling of DNA copy number and methyl-
ation for deciphering biomarkers in non-small cell lung
cancer patients. Cancer Lett 311:29-37, 2011
36. Nelson HH, Marsit CJ, Christensen BC, et al:
Key epigenetic changes associated with lung cancer
development: Results from dense methylation array
profiling. Epigenetics 7:559-566, 2012
37. Alaminos M, Davalos V, Cheung NK, et al:
Clustering of gene hypermethylation associated
with clinical risk groups in neuroblastoma. J Natl
Cancer Inst 96:1208-1219, 2004
38. Di Vinci A, Casciano I, Marasco E, et al:
Quantitative methylation analysis of HOXA3, 7, 9,
and 10 genes in glioma: Association with tumor
WHO grade and clinical outcome. J Cancer Res Clin
Oncol 138:35-47, 2012
39. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al:
Identification of 20 genes aberrantly methylated in hu-
man breast cancers. Int J Cancer 116:407-414, 2005
40. Cottrell S, Jung K, Kristiansen G, et al: Discovery
and validation of 3 novel DNA methylation markers of
prostate cancer prognosis. J Urol 177:1753-1758, 2007
41. Ramalingam SS, Maitland ML, Frankel P, et al:
Carboplatin and paclitaxel in combination with either
vorinostat or placebo for first-line therapy of advanced
non-small-cell lung cancer. J Clin Oncol 28:56-62, 2010
42. Juergens RA, Wrangle J, Vendetti FP, et al:
Combination epigenetic therapy has efficacy in pa-
tients with refractory advanced non-small cell lung
cancer. Cancer Discov 1:598-607, 2011
Affiliations
Juan Sandoval, Jesus Mendez-Gonzalez, F. Javier Carmona, Sergi Sayols, Sebastian Moran, Holger Heyn, Miguel Vizoso, Antonio Gomez, Montse
Sanchez-Cespedes, and Manel Esteller, Bellvitge Biomedical Research Institute; Josefina Mora, Hospital de la Santa Creu i Sant Pau; Manel Esteller,
UniversityofBarcelonaandInstitucioCatalanadeRecercaiEstudisAvanc¸ats,Barcelona;MiquelTaronandRafaelRosell,CatalanInstituteofOncology,
Badalona, Catalonia; Marina Pollan, Instituto de Salud Carlos III, Madrid; Maria J. Pajares and Luis M. Montuenga, University of Navarra; Wenceslao
Torre, Clínica University de Navarra, Pamplona, Spain; Ernest Nadal, Guoan Chen, and David G. Beer, University of Michigan Medical School, Ann
Arbor, MI; Yassen Assenov and Fabian Mu¨ller, Max Planck Institute, Saarbru¨cken, Germany; Christoph Bock, Center for Molecular Medicine of the
Austrian Academy of Sciences, Vienna, Austria; Lucia A. Muscarella, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo della
Sofferenza, San Giovanni Rotondo, Italy; Triantafillos Liloglou, Michael Davies, and John K. Field, The University of Liverpool Cancer Research Centre,
Liverpool, United Kingdom; Elisabeth Brambilla, Centre Hospitalier Universitaire A Michallon, Grenoble, France; Luca Roz, IRCCS Foundation
National Cancer Institute, Milan; Marco Lo Iacono and Giorgio V. Scagliotti, University of Torino, Orbassano (Torino), Italy.
■ ■ ■
Clinical Value of DNA Methylation in NSCLC
www.jco.org © 2013 by American Society of Clinical Oncology 4147
from 130.192.222.19
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on June 21, 2016
Copyright © 2013 American Society of Clinical Oncology. All rights reserved.
Acknowledgment
We thank Diana García, Carles Arribas, Vito Michele Fazio, Annamaria la Torre, and Ruben Pio for their support.
Sandoval et al
© 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
from 130.192.222.19
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on June 21, 2016
Copyright © 2013 American Society of Clinical Oncology. All rights reserved.
